News
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Outlook for fiscal year 2026 and update of mid-term guidance
SCHOTT Pharma AG & Co. KGaA issues fiscal year 2026 outlook and updates mid-term guidance, projecting revenue growth of 2-5% and EBITDA margin around 27%. Market expectations differ -
-
-
-
-
-
-
-